Biotech Firm Telix Pharmaceuticals Pulls US IPO

117
SHARE
Telix Pharmaceuticals Pulls US IPO

Australian biotechnology firm Telix Pharmaceuticals Ltd., whose U.S. shares were set to debut trading on Friday, canceled plans for an estimated $202 million U.S. initial public offering, citing unfavorable market conditions.

Telix Pharmaceuticals Pulls US IPO : Initial Plans and Pricing

Melbourne-based Telix intended to raise about $202 million by offering 17 million shares at $11.87 each, a price similar to recent trading on the Australian Securities Exchange, where the company is already listed. Telix said it decided against proceeding with a U.S. IPO because investors sought discounts below its preferred pricing levels. U.S. shares of Telix were set to trade on the Nasdaq exchange under the symbol “TLX.”

Telix Pharmaceuticals Pulls US IPO : Decision to Withdraw

“Given the proposed Nasdaq listing was not predicated on the need to raise capital, Telix’s management and board of directors have decided not to move forward with the transaction at the terms provided under current market conditions,” Telix said in a statement released late on Thursday. “The company did not feel that the proposed discounts were aligned with its duty to its existing shareholders.”

Legal Representation

WilmerHale represented Telix on U.S. legal matters, while Herbert Smith Freehills LLP represented the company on Australian legal matters on the IPO. Latham & Watkins LLP was representing the underwriters on U.S. legal matters, while Allens represented underwriters on Australian legal matters.

Reasons for U.S. Listings

Foreign companies often seek to list in the U.S. seeking a deeper pool of investors that are available here compared with their home markets. U.S. listings can also provide more liquidity for shareholders, while increasing opportunities for future capital raises.

Telix Pharmaceuticals Pulls US IPO : Use of Proceeds

Telix had said proceeds from its U.S. IPO would fund development of drugs treating kidney and brain cancer and to expand its global supply chain and manufacturing capabilities. The commercial-stage company develops therapeutic and diagnostic radiopharmaceuticals, describing itself as a “profitable, cash generative” business.